Condition

Residual Disease clinical trials and research

• 2Clinical trials
• 1Country

All recruiting trials (2)

• ctDNA surveillance with Dato-DXd for people with high-risk early triple-negative breast cancer and residual disease

  This study will test whether regular blood-based ctDNA monitoring can find tiny relapses in adults with stage II/III triple-negative breast cancer who have residual disease after neoadjuvant therapy and whether early treatment with Dato-DXd when ctDNA becomes positive can reduce recurrence.

  Recruiting Phase 2 UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT07069595

• Combining Tetrathiomolybdate with Capecitabine for Triple Negative Breast Cancer

  This study is testing if adding a new drug called tetrathiomolybdate to the usual treatment for high-risk triple negative breast cancer can help patients who still have cancer after their initial therapy.

  Recruiting at 2 sites Phase 1/2 Dartmouth-Hitchcock Medical Center · Indianapolis, Indiana and 2 other locations · NCT06134375

Related topics

Quick answers

How many Residual Disease clinical trials are recruiting right now?

2, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

All of them have sites in United States. Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1/2: 1, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →